Walleye Capital’s Krystal Biotech KRYS Stock Holding History

Walleye Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Buy	4,200 +3,600	+600%	+$1.08M	0.01%	1733
2026 Q1	$155K	Buy	+600	New	+$160K	﹤0.01%	3474
2025 Q1	–	Sell	-4,000	Closed	-$627K	–	4694
2024 Q4	$627K	Buy	4,000 +1,900	+90%	+$337K	﹤0.01%	2802
2024 Q3	$382K	Buy	2,100 +700	+50%	+$135K	﹤0.01%	3539
2024 Q2	$257K	Buy	+1,400	New	+$235K	﹤0.01%	4109
2023 Q3	–	Sell	-3,900	Closed	-$458K	–	5118
2023 Q2	$458K	Buy	3,900 +600	+18%	+$61.3K	﹤0.01%	2510
2023 Q1	$264K	Buy	+3,300	New	+$259K	﹤0.01%	2228
2022 Q4	–	Sell	-700	Closed	-$49K	–	3424
2022 Q3	$49K	Buy	+700	New	+$50.6K	﹤0.01%	2587

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Walleye Capital's KRYS Position: Q2 2026 in Review

Walleye Capital reduced its Krystal Biotech (KRYS) stake by 97% in Q2 2026, selling an estimated $102K and leaving 12 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #4545.

Walleye Capital first reported a position in KRYS in Q3 2024 and has held it in 3 quarters since. The position peaked at $91.4K in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Walleye Capital held 12 shares of Krystal Biotech worth $4.46K as of Q2 2026.
Walleye Capital sold 342 Krystal Biotech shares in Q2 2026, an estimated $102K.
Krystal Biotech made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4545 holding.
Walleye Capital first reported a position in Krystal Biotech in Q3 2024 and has held it in 3 quarters since.
Walleye Capital's Krystal Biotech position peaked at $91.4K in Q1 2026.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.